Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2008-09-17

Last Posted Date: 2016-10-04

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 50

Registration Number: NCT00753909

Locations: 🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷
Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

and more 7 locations

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell of the Head and Neck

First Posted Date: 2008-09-16

Last Posted Date: 2014-11-04

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 14

Registration Number: NCT00753038

Locations: 🇺🇸
Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Phase I Study of TAS-106 in Combo With Carboplatin

Phase 1

Completed

Conditions: Cancer
Solid Tumors

Interventions: Drug: TAS-106
Drug: Carboplatin

First Posted Date: 2008-09-12

Last Posted Date: 2012-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT00752011

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-09-10

Last Posted Date: 2011-05-23

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 50

Registration Number: NCT00750386

Locations: 🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷
University Hospital of Crete, Heraklion, Crete, Greece
🇬🇷
"IASO" General Hospital of Athnes, Dep of Medical Oncology, Athens, Greece

and more 9 locations

Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children

Phase 2

Completed

Conditions: Medulloblastomas
Ependymomas
Supratentorial PNETs
Recurrent Brain Tumors

Interventions: Drug: temozolomide
Drug: carboplatin
Drug: temozolomide, thiotepa
Drug: etoposide
Drug: thiotepa, carboplatin, etoposide
Procedure: autologous stem cell transplantation
Drug: intraventricular etoposide
Drug: trofosfamide, etoposide

First Posted Date: 2008-09-09

Last Posted Date: 2018-07-20

Lead Sponsor: University Hospital, Bonn

Target Recruit Count: 174

Registration Number: NCT00749723

Locations: 🇩🇪
Universitätskinderklinik Freiburg, Freiburg, Germany
🇩🇪
Universitätskinderklinik Göttingen, Göttingen, Germany
🇩🇪
Universitätskinderklinik Heidelberg, Heidelberg, Germany

and more 51 locations

Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer
Peritoneal Cavity Cancer
Fallopian Tube Cancer

Interventions: Drug: carboplatin
Drug: decitabine

First Posted Date: 2008-09-08

Last Posted Date: 2013-07-10

Lead Sponsor: Cancer Research UK

Target Recruit Count: 134

Registration Number: NCT00748527

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Hammersmith Hospital, London, England, United Kingdom
🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom

and more 8 locations

Bevacizumab and Carboplatin for Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2008-09-01

Last Posted Date: 2016-11-16

Lead Sponsor: Vejle Hospital

Target Recruit Count: 73

Registration Number: NCT00744718

Locations: 🇩🇰
Vejle Hospital, Vejle, Denmark

Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Ixabepilone
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2008-08-27

Last Posted Date: 2021-12-15

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 82

Registration Number: NCT00741988

Locations: 🇺🇸
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸
Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

and more 10 locations

Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: Vinorelbine
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2008-08-20

Last Posted Date: 2011-04-04

Lead Sponsor: The Norwegian Lung Cancer Study Group

Target Recruit Count: 444

Registration Number: NCT00737867

Locations: 🇳🇴
Øystein Fløtten, Bergen, Norway
🇳🇴
Sverre Fluge, Haugesund, Norway
🇳🇴
Tore Amundsen, Trondheim, Norway

and more 1 locations

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Phase 2

Completed

Conditions: Carcinoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Erlotinib
Other: Treatment determined by physician
Drug: Bevacizumab

First Posted Date: 2008-08-18

Last Posted Date: 2016-08-17

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 289

Registration Number: NCT00737243

Locations: 🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸
Wellstar Cancer Research, Marietta, Georgia, United States
🇺🇸
Integrated Community Oncology Network, Jacksonville, Florida, United States

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy